The Global Kidney Cancer Drugs Market Is Witnessing High Growth Owing To the Increasing Prevalence of Kidney Cancer Cases in the World
Market
Overview:
Kidney cancer is a serious medical
condition. There are several types of the disease, including medullary and
sarcoma, which are less common but highly aggressive. They develop in the soft
tissue surrounding the kidney, as well as in the fat that surrounds it.
Surgical removal of the affected organ is the standard treatment for this type
of cancer. However, if the disease has spread to other organs or spreads beyond
the kidney, chemotherapy or systemic therapy may be needed. A biopsy is another
test for kidney cancer. It involves inserting a thin needle into a tumor and
looking through the tissue under a microscope to detect cancer cells. Biopsies
aren't always accurate, and the healthcare provider may not recommend them. If
the tumor has spread to lymph nodes or is large, a biopsy may be performed.
This will allow the doctor to evaluate the tumor's location and the extent of
its spread and determine its stage and aggressiveness.
Competitive
Landscape:
Major players operating in the global
kidney cancer drugs market include Quest Diagnostics Incorporated, Illumina
Inc, Rosetta Genomics, Sysmex Corporation, NanoString Technologies Inc,
NeoGenomics Laboratories, Myriad Genetics Inc, Argos Therapeutics, Prometheus
Laboratories, Immatics Biotechnologies, Aveo Pharmaceuticals, Abbott
Laboratories, Onyx, Cipla Limited, Roche, Eisai, Bristol-Myers Squibb, Thermo
Fisher Scientific Inc, Amgen, Active Biotech, GlaxoSmithKline Plc, Genentech
Inc., F. Hoffmann-La Roche Ag, Exelixis Inc, Novartis International AG, Pfizer
Inc., and Bayer AG.
Key
Market Drivers:
The increasing incidence of kidney cancer
cases in the world is expected to augment the growth of the global kidney
cancer drugs market. For instance, according to Cancer.Net, in 2020, around
431,288 individuals in the world were suffering from kidney cancer. Targeted
drug therapy uses drugs or substances to attack the cancer cells in a specific
area of the body. This can reduce side effects caused by the drugs while still
killing the cancer cells. Anti-angiogenic agents block the growth of the blood
vessels feeding the tumor. A multikinase inhibitor can stop the growth of
cancer cells, while a tyrosine kinase inhibitor works by blocking an enzyme
that helps the cancer cells grow. Increasing treatment launches by key players
are estimated to enhance the growth of the global kidney cancer drugs
market.
Covid-19
Impact Analysis
During the COVID-19 pandemic, the
increasing focus on the virus-infected cases affected the growth of the global
kidney cancer drugs market. Moreover,
sudden stress on the healthcare sector also impacted the market growth.
Key
Takeaways
·
North
America is expected to dominate the growth of the global kidney cancer drugs
market, owing to the increasing prevalence of kidney cancer cases in the
region. For instance, according to Cancer.Net, in 2020 around 79,000 adults in
the U.S. were diagnosed with kidney cancer.
·
The
Asia Pacific is estimated to witness high growth in the global kidney cancer
drugs market, owing to the increasing expansion of cancer hospitals in the
region. For instance, according to the Indian Cancer Society, India has around
27 dedicated cancer hospitals currently.
Comments
Post a Comment